Identifying CTCs and actionable biomarkers can help to confirm CNS involvement when clinically suspected, characterize tumor mutational evolution, guide targeted therapy selection and potentially monitor for treatment response and tumor burden.

Conclusions

- Target Selector™ is a viable and sensitive platform for CTC detection and molecular analysis of cfDNA samples from patients with NSCLC or breast cancer with CNS metastases compared to the current standard of care (CSF cytology)
- Identifying CTCs and actionable biomarkers can help to confirm CNS involvement when clinically suspected, characterize tumor mutational evolution, guide targeted therapy selection and potentially monitor for treatment response and tumor burden.

References